Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced Thursday.
MiroBio sprouted from a University of Oxford research laboratory run by professors Simon Davis and Richard Cornall. Its approach focuses on checkpoint receptors, proteins that help to regulate the immune system.
Blocking these proteins has proven effective in treating cancer, unleashing the immune system to attack malignant cells. But companies like MiroBio are exploring how they can be targeted to tamp down damaging immune system overreactions in inflammatory diseases. READ MORE
by Gwendolyn Wu
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.